

**HEXTAR HEALTHCARE BERHAD (199601000297) (372642-U)**

Condensed Consolidated Statements of Comprehensive Income for the fourth quarter ended 31 December 2025

These figures have not been audited

	Individual Period		Cumulative Period	
	2025 Current Year Quarter ended 31 December RM'000	2024 Preceding Year Quarter ended 31 December RM'000	2025 Current Year to-Date ended 31 December RM'000	2024 Preceding Year to-Date ended 31 December RM'000
Revenue	35,536	41,654	148,114	146,950
Cost of sales	(39,827)	(54,337)	(156,415)	(156,400)
Gross Loss	(4,291)	(12,683)	(8,301)	(9,450)
Other gains and losses	(11,226)	7,388	(11,210)	8,159
Operating expenses	(3,930)	(4,064)	(13,905)	(15,082)
Loss from operations	(19,447)	(9,359)	(33,416)	(16,373)
Finance costs	(69)	(117)	(339)	(266)
Share of losses in an associate	(1,695)	(1,158)	(3,725)	(2,342)
Loss before tax	(21,211)	(10,634)	(37,480)	(18,981)
Income tax (expense)/credit	(10,175)	2,644	(7,476)	5,061
LOSS FOR THE PERIOD ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY	(31,386)	(7,990)	(44,956)	(13,920)
Other comprehensive income, net of tax:				
Foreign currency translation differences for foreign operations	(805)	201	439	(1,870)
Changes in fair value of other assets	(11,557)	(38,648)	(11,557)	(38,648)
Total comprehensive loss for the period attributable to Equity holders of the Company	(43,748)	(46,437)	(56,074)	(54,438)
Loss per share:				
Basic (sen)	(2.85)	(0.76)	(4.08)	(1.33)
Weighted average number of shares	1,102,110,781	1,044,750,114	1,102,110,781	1,044,750,114

The condensed consolidated statements of comprehensive income should be read in conjunction with the audited financial statements for the year ended 31 December 2024 and the accompanying notes attached to the interim financial statements.

**HEXTAR HEALTHCARE BERHAD (199601000297) (372642-U)**

Condensed Consolidated Statements of Financial Position as of 31 December 2025

These figures have not been audited

	As of 31 December 2025 RM'000	As of 31 December 2024 RM'000
ASSETS		
Non-current Assets		
Property, plant and equipment	167,490	174,167
Prepaid lease payments	4,440	16,336
Deferred tax asset	5,818	12,855
Other investments	163,054	178,626
Right-of-use assets	4,121	2,819
	<u>344,923</u>	<u>384,803</u>
Current Assets		
Inventories	44,362	63,862
Trade receivables	20,121	19,077
Other receivables	45,987	62,166
Cash and bank balances	23,872	9,217
	<u>134,342</u>	<u>154,322</u>
TOTAL ASSETS	<u><u>479,265</u></u>	<u><u>539,125</u></u>
EQUITY AND LIABILITIES		
Equity attributable to equity holders of the Company		
Issued capital	361,387	361,387
Treasury shares	(48,191)	(48,191)
Other reserves	(49,234)	(38,116)
Retained earnings	188,034	232,990
TOTAL EQUITY	<u>451,996</u>	<u>508,070</u>
Non-current Liabilities		
Borrowings	11	115
Lease liabilities	1,544	1,688
Deferred tax liabilities	2,079	1,933
	<u>3,634</u>	<u>3,736</u>
Current Liabilities		
Trade payables	8,420	10,300
Other payables	12,542	15,095
Lease liabilities	2,613	1,252
Borrowings	60	672
	<u>23,635</u>	<u>27,319</u>
TOTAL LIABILITIES	<u>27,269</u>	<u>31,055</u>
TOTAL EQUITY AND LIABILITIES	<u><u>479,265</u></u>	<u><u>539,125</u></u>
Net asset per share (RM)	0.42	0.46

The condensed consolidated statements of financial position should be read in conjunction with the audited financial statements for the year ended 31 December 2024 and the accompanying notes attached to the interim financial statements.



HEXTAR HEALTHCARE BERHAD (199601000297) (372642-U)

Condensed Consolidated Statements of Changes in Equity for the fourth quarter ended 31 December 2025
 These figures have not been audited

	Attributable to Equity Holders of the Company						Total Equity RM'000
	Share Capital RM'000	Treasury Shares RM'000	Revaluation Reserves RM'000	Fair Value Reserves RM'000	Translation Reserves RM'000	Retained Earnings RM'000	
As at 01 January 2024	341,308	(48,191)	413	-	1,989	246,910	542,429
Total comprehensive loss for the period	-	-	-	-	-	(13,920)	(13,920)
Issuance of new shares	20,079	-	-	-	-	-	20,079
Changes in fair value of other assets	-	-	-	(38,648)	-	-	(38,648)
Effects of foreign exchange differences	-	-	-	-	(1,870)	-	(1,870)
As at 31 December 2024	361,387	(48,191)	413	(38,648)	119	232,990	508,070
As at 01 January 2025	361,387	(48,191)	413	(38,648)	119	232,990	508,070
Total comprehensive loss for the period	-	-	-	-	-	(44,956)	(44,956)
Changes in fair value of other assets	-	-	(229)	(11,328)	-	-	(11,557)
Effects of foreign exchange differences	-	-	-	-	439	-	439
As at 31 December 2025	361,387	(48,191)	184	(49,976)	558	188,034	451,996

The condensed consolidated statements of changes in equity should be read in conjunction with the audited financial statements for the year ended 31 December 2024 and the accompanying notes attached to the interim financial statements.

**HEXTAR HEALTHCARE BERHAD (199601000297) (372642-U)**

Condensed Consolidated Statements of Cashflows for the fourth quarter ended 31 December 2025

These figures have not been audited

	2025 Year ended 31 December RM'000	2024 Year ended 31 December RM'000
Loss before tax	(37,480)	(18,981)
Adjustments for non-cash flow items	34,130	37,895
Operating profit/(loss) before changes in working capital	<u>(3,350)</u>	<u>18,914</u>
(Increase)/Decrease in current assets:		
Inventories	16,718	(33,129)
Trade and other receivables	293	(4,260)
Increase/(Decrease) in current liabilities:		
Trade and other payables	<u>(4,302)</u>	<u>4,101</u>
Cash from/(used in) operations	9,359	(14,374)
Income tax refunded/(paid)	<u>9,137</u>	<u>(2,943)</u>
Nett cashflows from/(used in) operating activities	18,496	(17,317)
Cashflows from/(used in) investing activities:		
Advances to an associate	(7,103)	(12,897)
Purchase of property, plant and equipment	(6,621)	(5,151)
Proceeds from disposal of property, plant and equipment	12,031	478
Interests received	240	620
Nett cashflows used in investing activities	(1,453)	(16,950)
Cashflows from/(used in) financing activities:		
Proceeds from issuance of shares	-	20,079
(Repayment)/Drawdown of bills payable	(283)	283
Repayment of term loan and hire purchase payables	(433)	(820)
Interests on borrowings paid	(224)	(526)
Repayment of lease liabilities	<u>(1,748)</u>	<u>(1,436)</u>
Nett cashflows from/(used in) financing activities	(2,688)	17,580
Nett increase/(decrease) in cash and cash equivalents	14,355	(16,687)
Cash and cash equivalents at beginning of financial period	8,797	25,650
Effect of foreign exchange differences	287	(166)
Cash and cash equivalents at end of financial period	<u>23,439</u>	<u>8,797</u>
Cash and cash equivalents at end of financial period comprise the following:		
Cash and bank balances	23,872	9,217
Less: Fixed deposits pledged to bank	<u>(433)</u>	<u>(420)</u>
	<u>23,439</u>	<u>8,797</u>

The condensed consolidated statements of cashflows should be read in conjunction with the audited financial statements for the year ended 31 December 2024 and the accompanying notes attached to the interim financial statements.



NOTES TO THE INTERIM FINANCIAL REPORT FOR THE FOURTH QUARTER ENDED 31 DECEMBER 2025

A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARD (“MFRS”) 134: INTERIM FINANCIAL REPORTING

1. Basis of Preparation of the Financial Statements and Adoption of New and Revised Malaysian Financial Reporting Standards (“MFRSs”)

The interim financial report is unaudited and has been prepared in accordance with Malaysian Financial Reporting Standard (MFRS) 134: Interim Financial Reporting and paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad and should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 December 2024.

The accounting policies and methods of computation adopted for the interim financial statements were consistent with those adopted for the annual audited financial statements for the year ended 31 December 2024.

2. Auditor’s Report on Preceding Annual Financial Statements

The auditor’s report on the financial statements of the Group and the Company for the previous year ended 31 December 2024 was not subject to any qualification.

3. Seasonal or Cyclical Factors

The Group’s products are not materially impacted by any seasonal or cyclical factors.

4. Unusual Items due to their Nature, Size or Incidence

There were no unusual items affecting the Group’s assets, liabilities, equity, net income or cash flows in the financial statements for the period ended 31 December 2025.

5. Changes in Material Estimates

There were no changes in the nature and computation of estimates reported in prior financial year(s) that have a material effect in the financial statements for the period ended 31 December 2025.

6. Changes in Debt and Equity Securities

6.1 Share Buy-back

The Company did not carry out any Share Buy-back in the current financial year.

As of 31 December 2025, a total of 91,273,100 shares were held as Treasury Shares by the Company, and the net number of issued shares was 1,102,110,781 shares.

7. Dividends Paid

No dividends have been declared by the Company in respect of the current financial year.



8. Segmental Information

Segmental information is presented in accordance to business operating activities, which is the Group's primary reporting format.

	Gloves Operation RM'000	Medical Devices Operation RM'000	Property Investment RM'000	Current quarter ended 31 Dec 2025 RM'000	Cumulative year-to-date RM'000
Revenue	33,664	1,872	-	35,536	148,114
Segment Results	(7,958)	74	(13,313)	(21,197)	(37,260)
Investment Income	45	9	-	54	119
Finance Costs	(50)	(19)	-	(69)	(339)
Profit/(Loss) before Tax	(7,962)	64	(13,313)	(21,211)	(37,480)
Tax Expense	(10,175)	-	-	(10,175)	(7,476)
Profit/(Loss) after Tax	(18,137)	64	(13,313)	(31,386)	(44,956)

9. Valuation of Property, Plant and Equipment

The Group did not carry out any revaluations on its property, plant and equipment in the current quarter and financial year ended 31 December 2025.

The values of property, plant and equipment have been brought forward without amendment from the previous annual financial statements ended 31 December 2024.

10. Subsequent Events

There were no events subsequent to the end of the current quarter that have not been reflected in the financial period ended 31 December 2025, save for the allotment of 6,600 new ordinary shares in an associated company, Alliance Empire Sdn Bhd in January 2026, resulting in a dilution of shareholding from 20.0% to 19.9% in the Company's wholly-owned subsidiary, Rubberex Empire Sdn Bhd, due to the non-participation in additional capital funding.

11. Changes in the Composition of the Group

There were no changes to the composition of the Group including business combinations, acquisition or disposal of subsidiaries and long-term investments, restructuring and discontinuing operations since the last audited financial year ended 31 December 2024.

12. Changes in Contingent Liabilities or Contingent Assets

There were no changes in contingent liabilities or assets since the last audited annual balance sheet date of 31 December 2024.

13. Capital Commitments

There was no commitment for the purchase of property, plant and equipment not provided for in the financial statements for the period ended 31 December 2025.



B. ADDITIONAL INFORMATION PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD

1. Review of Performance

The Group recorded a revenue of RM35.5 million in the current quarter compared to RM41.6 million in the corresponding quarter ended 31 December 2024, a decrease of RM6.1 million or 14.7%. Loss before tax in the current quarter amounted to RM21.2 million compared to RM10.6 million in the corresponding period of the previous year, as the Group recognized an impairment loss on investment of RM11.6 million in the current quarter.

For the full financial year, the Group recorded a cumulative revenue of RM148.1 million, a slight increase of RM1.1 million from RM147.0 million in the corresponding period of previous year. Pretax loss amounted to RM37.5 million, which had increased by RM18.5 million or 97.4% from RM19.0 million in the previous year, attributable to the impairment loss on investment, low capacity utilization of the glove plants, higher operational costs and strong Ringgit exchange. Overall, the Group recorded a net loss of RM44.9 million, an increase from RM13.9 million previously as an adjustment for deferred tax assets of RM10.7 million was also taken up in the current year.

2. Material change in profits of the current quarter compared with preceding quarter

The Group recorded a loss after tax in the current fourth quarter of RM31.4 million, compared to RM5.8 million in the preceding third quarter of the year, an increase of RM25.6 million, mainly attributable to the impairment loss on investment as well as deferred tax adjustments taken up in the current year.

3. Current Year Prospects

The Group's glove and medical devices businesses are expected to remain challenging in the short to medium term, amidst global trade uncertainties, foreign exchange risks and rising material prices, energy and labour costs. However, the Group remains committed to its core businesses and is focused on driving revenue, increasing operational efficiency and maintaining effective cost controls at its key operational divisions for financial year 2026.

4. Profit Forecast or Profit Guarantee

No profit forecast or profit guarantee has been issued for the current quarter.

5. Taxation (expense)/credit

	Current quarter ended 31 Dec 2025 RM'000	Cumulative year- to-date RM'000
Current year – Malaysian income tax	484	(149)
Current year – Foreign income tax	(31)	(144)
Deferred tax	(10,628)	(7,183)
Total income tax expense	(10,175)	(7,476)

**6. Sales of Unquoted Investments and/or Properties**

There were no sales of unquoted investments and/or properties in the current quarter ended 31 December 2025.

7. Purchase/disposal of Quoted Securities

There were no purchase and/or disposal of quoted securities for the current quarter ended 31 December 2025.

8. (a) Status of Corporate Proposals

There were no corporate proposals not announced or outstanding as of 31 December 2025.

(b) Status of Utilisation of Proceeds

(i) On 03 August 2023, the Company announced an extension of time and variation to the utilization of proceeds raised from an earlier Private Placement exercise amounting to RM66.0 million:

Purpose	Proposed Utilisation RM'000	Variation in Utilisation of Proceeds * RM'000
1. Acquisition of double-formers nitrile disposable glove production lines	66,024	-
2. Working capital	-	15,744
3. Fixed or short-term deposits – earmarked for future investments ^	-	50,280
4. Estimated expenses	558	-
Total	66,582	66,024

* As announced on 03 August 2023

^ RM50.3 million had partially been utilised in the Group's property investment division, as well as in the purchase of property, plant and equipment, and working capital in 2025.

As of 31 December 2025, the proceeds have been fully utilized.

(ii) With regards to the proposed private placement of 100,191,000 shares which had been approved by Bursa Malaysia on 02 April 2024, a total of 100,191,000 Placement Shares had been issued pursuant to the Private Placement with total net proceeds of RM20.0 million raised and utilized as of 31 December 2025.

Purpose	Proposed Utilisation RM'000	Actual Utilization RM'000
Working capital	19,838	19,838
Estimated expenses	200	200
Total	20,038	20,038



9. Group Borrowings and Debt Securities

	As of 31 December 2025		
	Secured RM'000	Unsecured RM'000	Total RM'000
Current	-	60	60
Non-current	-	11	11
	-	71	71

10. Financial Instruments Risks

As of 31 December 2025, the Group has the following foreign currency contracts outstanding: -

	Contracted Amount '000	Ringgit Equivalent RM'000	Fair Value RM'000
U.S. Dollar (USD)	466	1,919	1,918
Euro (EUR)	177	850	845

The above foreign currency contracts were entered into with local licensed banks to hedge the Group's receivables and payables in foreign currencies. The contracted rates will be used to translate the underlying foreign currencies into Ringgit Malaysia.

These foreign currency contracts are of a short-term nature. The accounting policy adopted with regards to off balance sheet financial instruments was consistent with those applied in the last audited financial statements as of 31 December 2024.

11. Changes in Material Litigation

There was no outstanding material litigation as of 31 December 2025.

12. Dividend Payable

No dividend is proposed for the current quarter ended 31 December 2025.

13. Loss per Share

		Cumulative Year-to-Date ended 31 December 2025	Cumulative Year-to-Date ended 31 December 2024
Loss for the period attributable to equity holders of the Company	RM'000	(44,956)	(13,920)
Weighted average number of ordinary shares in issue	Shares	1,102,110,781	1,044,750,114
Loss per share	sen	(4.08)	(1.33)

14. Authorisation for Issue

The interim financial statements and explanatory notes were authorised for issue by the Board of Directors on 23 February 2026.